Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Eftilagimod Alpha + Pembrolizumab in Soft tissue sarcoma. The expected timing is based on the latest available company guidance and may change.
07/30/26:- EFTISARC-NEO HRQoL ESMO 2026 presentation reiterated; disease-free survival follow-up continues.
Verification
Confirm timing and program details against the company announcement or filing.